Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Current Atherosclerosis Reports

Issue 1/2001

Content (16 Articles)

Invited Commentary

Impact of lifestyle changes on plasma lipid levels and ischemic disease

Tamio Teramoto

Literature alert

Roger S. Blumenthal

Web alert

Statin trials in progress: Unanswered questions

Michael H. Davidson

New statins and new doses of older statins

Evan A. Stein

Diabetes: Statins, fibrates, or both?

Michel Farnier, Sylvie Picard

Statins in children: What do we know and what do we need to do?

Donald M. Black

Statins, hormones, and women: Benefits and drawbacks for atherosclerosis and osteoporosis

David M. Herrington, Karen Potvin Klein

Clinical trials report

Daniel Eisenberg

Soy proteins and cardiovascular disease

Cesare R. Sirtori, Maria R. Lovati

Diagnosis and treatment of hyperhomocysteinemia

Mary E. Keebler, Cyrus De Souza, Vivian Fonseca

Antiatherogenic components of olive oil

Francesco Visioli, Claudio Galli

Effects of fish oils and fish on cardiovascular disease

Paul Nestel

The benefits of niacin in atherosclerosis

S. Tavintharan, Moti L. Kashyap

The role of fibric acids in atherosclerosis

Jean-Charles Fruchart, Bart Staels, Patrick Duriez

Herbs and atherosclerosis

David Heber

Dec 00
Issue: 1/2000
Mar 01
Issue: 2/2001

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits